Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.fiercebiotech.com/biotech/selecta-fuses-cartesian-reverse-merger-bolstering-finances-autoimmune-cell-therapy-goals
https://www.globenewswire.com//news-release/2023/11/13/2779033/0/en/Selecta-Biosciences-Announces-Merger-with-Cartesian-Therapeutics.html
https://www.globenewswire.com//news-release/2023/10/31/2770616/0/en/Selecta-Announces-Transition-of-Manufacturing-and-Clinical-Operations-of-ImmTOR-for-SEL-212-to-Commercialization-Partner-Sobi.html
https://www.globenewswire.com//news-release/2023/08/17/2727105/0/en/Selecta-Biosciences-Reports-Second-Quarter-2023-Financial-Results-and-Updates-on-Strategic-Initiative-Designed-to-Maximize-Stockholder-Value-Associated-with-SEL-212-Economics.html
https://www.fiercebiotech.com/biotech/selecta-narrows-focus-gout-drug-freezing-investment-rest-pipeline
https://www.globenewswire.com/news-release/2023/05/31/2679221/0/en/Selecta-Biosciences-Announces-Presentation-of-Data-from-Phase-3-DISSOLVE-Program-of-SEL-212-in-Chronic-Refractory-Gout-During-Late-Breaking-Session-at-the-EULAR-2023-European-Congr.html
https://endpts.com/selecta-lays-off-25-of-employees-after-strategic-review/
https://www.globenewswire.com/news-release/2023/05/04/2661387/0/en/Selecta-Biosciences-Reports-First-Quarter-2023-Financial-Results-and-Provides-Business-Update.html
https://www.fiercebiotech.com/biotech/planning-challenge-horizon-selecta-and-sobi-rout-gout-pair-phase-3-trials
https://www.globenewswire.com/news-release/2023/03/21/2630995/0/en/Phase-3-DISSOLVE-Program-of-SEL-212-in-Chronic-Refractory-Gout-Meets-Primary-Endpoint.html